PACLITAXEL AND CURCUMIN CO-LOADED MIXED MICELLES AS POTENTIAL NANOVEHICLES FOR BREAST AND OVARIAN CANCER THERAPY

MORETTON, MARCELA A.; BERNABEU E; CALIENNI, M. N.; CALABRO V; RIEDEL J; PRIETO, M. J.; GONZALEZ L.; MARTINEZ, C. S.; ALONSO, S. DEL V.; MONTANARI, JORGE; EVELSON P; CHIAPPETTA, DIEGO A.

Buenos Aires

Jornada; XX Jornadas Anuales de la Sociedad Argentina de Biología (SAB), XVII Jornadas de la Sociedad Uruguaya de Biociencias (SUB) y Segundas Jornadas Rioplatenses de Biología; 2018

Sociedad Argentina de Biología (SAB) y Sociedad Uruguaya de Biociencias (SUB)

Breast and ovarian cancer represent the first and the fifth cause of death among women worldwide. Paclitaxel (PTX) is one of the most effectiveantineoplastic drugs against breast and ovarian cancer while curcumin (CUR), a well known antioxidant agent, has been also proposed as a potentialantineoplastic drug. In this context, we aimed to explore the potential of a nanotechnological platform based in mixed polymeric micelles (PMs) toco-encapsulate paclitaxel (PTX) and curcumin (CUR), employing two commercially available biopolymers as Soluplus® and d-α-Tocopherylpolyethylene glycol 1000 succinate (TPGS). This multifunctional nanocarrier could overcome the poor water-solubility of PTX and minimize one ofits main side effects as the peripheral neuropathy, due to the incorporation of CUR, as an attempt to optimize breast and ovarian cancer therapy. Inthe first place, the PMs could successfully encapsulate both drugs (2 mg/mL of PTX and CUR) where the drug-loaded PMs exhibited a narrow sizedistribution with a hydrodynamic diameter of 96.0±1.2 nm. In a second step, the encapsulation of CUR within PMs did not affect its antioxidantactivity. Indeed, PTX-CUR-loaded micelles showed a significant increment (p